<DOC>
	<DOCNO>NCT03098550</DOCNO>
	<brief_summary>The purpose study determine whether combination nivolumab daratumumab safe effective treating advance tumor tumor spread</brief_summary>
	<brief_title>A Study Test Safety Effectiveness Nivolumab Combined With Daratumumab Patients With Advanced Solid Tumors Tumors That Have Spread</brief_title>
	<detailed_description />
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Patients metastatic advance solid tumor Women histologically cytologically confirm triple negative breast carcinoma Participants histologically cytologically confirm pancreatic adenocarcinoma Participants histologically cytologically confirm Non Small Cell Lung Cancer ( NSCLC ) Active brain metastasis leptomeningeal metastasis . Any serious uncontrolled medical disorder Prior malignancy active within previous 3 year Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>Triple Negative Breast Cancer ( TNBC )</keyword>
	<keyword>Pancreatic Cancer ( PAC )</keyword>
</DOC>